VivoSeq
Immunology

Crohn's Disease

92

Pipeline Programs↗

81

Active Trials↗

61

Companies Involved↗

Crohn's Disease is a moderately active landscape with 92 programs across 61 companies. The most active players are Amgen, Val Adams, Eastern Cooperative Oncology Group. 28 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

48/100

Mech. Concentration

13/100

Completion Rate

67/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1V

Val Adams

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1J

Jiangsu Carephar Pharmaceutical Co., Ltd.

3 programs

Phase 2Teva logo

Teva

2 programs

Phase 2EMD Serono logo

EMD Serono

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

55 of 78 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody1722%Protein / enzyme45%Peptide23%

Small molecule leads; the ring shows all 78 classified programs, each share of the total. Modality classified for 82% of 98 pipeline programs.

Analysis

Trial Status

369

clinical trials

Completed176 · 48%
Terminated71 · 19%
Recruiting51 · 14%
Unknown status25 · 7%
Active, not recruiting18 · 5%
Withdrawn15 · 4%
Other13 · 4%

Clinical Trials

Trial Activity

369 trials

Risankizumab in Children With Crohn's Disease (RisaKids)
Recruiting·SShaare Zedek Medical Center·N/A·NCT06298188·90 enrolled
Low Dose IL-2 for the Treatment of Crohn's Disease
Recruiting·—·Phase 1/2·NCT04263831·30 enrolled
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
Recruiting·—·Phase 4·NCT06180382·220 enrolled
Treatment of Moderate to Severe Refractory Crohn's Disease
Recruiting·TTr1X, Inc.·Phase 1/2·NCT06721962·39 enrolled
Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06972901·42 enrolled
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Recruiting·WWeill Medical College of Cornell University·Phase 3·NCT06274554·120 enrolled
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07444060·100 enrolled
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT05509777·90 enrolled
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
Recruiting·MMassachusetts General Hospital·N/A·NCT06252493·25 enrolled
Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients
Recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT06953791·52 enrolled
68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
Recruiting·MMayo Clinic·Phase 1·NCT07273188·45 enrolled
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting·AbbVie logoAbbVie·Phase 3·NCT05995353·110 enrolled
Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease
Recruiting·RRambam Health Care Campus·Phase 2·NCT05599347·180 enrolled
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Recruiting·—·Phase 4·NCT05781152·900 enrolled
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06681324·30 enrolled
Page 1 of 25

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)